FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA
Links shared publicly online about this topic.
- 567total visits
FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
View full resource at news-medical.net
Tags: Hepatitis B Medication, HIV, AIDS, HIV Medication, STD, FDA, Epivir, News
Most Recently Shared on January 20, 2011 at 2:21 pm By:
HIV/AIDS News: FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA: Mylan In... http://bit.ly/dXASt0
Advertisement
